Ki67 Is an Independent Predictor of Recurrence in the Largest Randomized Trial of 3 Radiation Fractionation Schedules in Localized Prostate Cancer

Anna C. Wilkins, FRCR,*,†,‡ Barry Gusterson, FRCPht,‡
Zsolt Szijgyarto, PhD,* Joanne Haviland, MSc,* Clare Griffin, MSc,*
Christine Stuttle, MPhil,† Frances Daley, MSc,‡
Catherine M. Corbishley, FRCPht,† David P. Dearnaley, FRCR,†,‡
Emma Hall, PhD,* and Navita Somaiah, DPhil,†,‡ on behalf of the CHHiP Trial Investigators

*Institute of Cancer Research-Clinical Trials and Statistics Unit, †Division of Radiotherapy and Imaging, and ‡Division of Breast Cancer Research, The Institute of Cancer Research, London, United Kingdom; and †The Royal Marsden, Sutton, London, United Kingdom

Received Dec 18, 2017, and in revised form Dec 27, 2017. Accepted for publication Jan 22, 2018.

Purpose: To assess whether the cellular proliferation marker Ki67 provides prognostic information and predicts response to radiation therapy fractionation in patients with localized prostate tumors participating in a randomized trial of 3 radiation therapy fractionation schedules (74 Gy/37 fractions vs 60 Gy/20 fractions vs 57 Gy/19 fractions).

Methods and Materials: A matched case-control study design was used; patients with biochemical/clinical failure >2 years after radiation therapy (BCR) were matched 1:1 to patients without recurrence using established prognostic factors.

Summary
Radiation therapy is delivered using uniform fractionation for localized prostate tumors despite varying recurrence rates. Biomarkers to guide treatment stratification and predict fraction size

Reprint requests to: Navita Somaiah, DPhil, The Institute of Cancer Research, 15 Cotswold Rd, Sutton SM2 5NG, United Kingdom. Tel: (+44) 2086613371; E-mail: navita.somaiah@icr.ac.uk

This work was supported by a Cancer Research UK Biomarkers and Imaging Discovery and Development Committee grant (number A21518) for Trans-CHHIP obtained in 2011. The CHHIP trial was funded by Cancer Research UK (CRUK/06/16, C8262/A7253, C1491/A9895, C1491/A15955, SP2312/021), the Department of Health and the National Institute for Health Research Cancer Research Network. A.C.W. was supported by a Cancer Research UK Clinical Research Fellowship. The authors also acknowledge Cancer Research UK Programme Grants for the Academic Radiotherapy Unit at the Institute of Cancer Research (C46/A10588 and C33589/A19727). Additional support for activities at the central receiving laboratory was provided by Prostate Cancer UK and the Movember Foundation. We acknowledge funding to the National Institute of Health Research (UK) Biomedical Research Centre at The Royal Marsden National Health Service Foundation Trust and The Institute of Cancer Research, London. The funding source(s) had no involvement in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.

D.P.D., E.H., and N.S. contributed equally to this work.

Conflict of interest: none.

Supplementary material for this article can be found at www.redjournal.org.

Acknowledgments—The authors thank the patients and all investigators and research support staff at the participating centers who contributed to the CHHIP trial; those who provided samples to Trans-CHHIP (Appendix); and Andrew Dodson for advice with Ki67 scoring methodology.
Introduction

Prostate cancer (PCa) is the second most common cancer worldwide for males; more than 1.11 million new cases were diagnosed in 2012 (1). In the developed world, increased prostate-specific antigen (PSA) testing means that most patients are diagnosed with localized disease, for which external beam radiation therapy (EBRT), brachytherapy, and prostatectomy are important radical treatment options.

Recurrence rates after EBRT for localized PCa vary considerably, from approximately 10% to 40-50% (2, 3). Recurrences are inadequately predicted using current prognostic algorithms that incorporate Gleason grade, T stage, and presenting PSA level. Identification of prognostic biomarkers to aid treatment stratification would therefore be clinically useful.

In addition, EBRT is delivered using a uniform fractionation schedule for all localized PCa (ie, a “one size fits all approach”). This is despite a wide variation in the biology of localized PCa (4), including proliferation rate (5). A personalized approach to fractionation therefore offers considerable potential to improve therapeutic outcomes. Biomarkers predicting sensitivity to radiation therapy fraction size have recently been identified as a key area for radiobiological research (6).

There is a tight inverse association between the proliferative indices of normal tissues and fractionation sensitivity. Tissues with high proliferation indices, such as gastrointestinal mucosa and epidermis, are insensitive to fraction size. In contrast, late-reacting normal tissues, such as kidney, have low proliferative indices and are very sensitive to fraction size (7, 8). This study tests the hypothesis that the same association between proliferative indices and fractionation sensitivity in normal tissues extends to localized PCa.

(Gleason score, prostate-specific antigen, tumor stage) and fractionation schedule. Immunohistochemistry was used to stain diagnostic biopsy specimens for Ki67, which were scored using the unweighted global method. Conditional logistic regression models estimated the prognostic value of mean and maximum Ki67 scores on BCR risk. Biomarker—fractionation interaction terms determined whether Ki67 was predictive of BCR by fractionation.

Results: Using 173 matched pairs, the median for mean and maximum Ki67 scores were 6.6% (interquartile range, 3.9%-9.8%) and 11.0% (interquartile range, 7.0%-15.0%) respectively. Both scores were significant predictors of BCR in models adjusted for established prognostic factors. Conditioning on matching variables and age, the odds of BCR were estimated to increase by 9% per 1% increase in mean Ki67 score (odds ratio 1.09; 95% confidence interval 1.04-1.15, P = .001). Interaction terms between Ki67 and fractionation schedules were not statistically significant.

Conclusions: Diagnostic Ki67 did not predict BCR according to fractionation schedule in CHHiP; however, it was a strong independent prognostic factor for BCR. © 2018 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
recommendations (9, 10). The centrally assigned Gleason grade was used for matching.

**Immunohistochemistry staining and scoring**

Full-face sections from the diagnostic biopsy blocks were used for immunohistochemistry staining. This decision followed a pilot study that demonstrated construction of tissue microarray, using the checkerboard technique (11), resulted in inadequate tumor cellularity (Tables E1 and E2; available online at www.redjournal.org). Immunohistochemistry staining methods are outlined in the Appendix (available online at www.redjournal.org). All slides were scored using bright-field microscopy by 2 independent investigators blinded to recurrence status and fractionation schedule. The CK5/6 basal marker distinguished preinvasive from invasive disease. Prostatic intraepithelial neoplasia and intraductal carcinoma were not scored. A minimum of 100 tumor cells were required to score each case.

The unweighted global assessment of Ki67 developed by the International Ki67 Working Group was used to score all prostate biopsies (12, 13). This includes assessment of intratumoral spatial heterogeneity, which is well recognized in localized PCa (14). The global assessment has met prespecified criteria for scoring reproducibility in an international phase 3 study using core biopsies of breast tumors (13). It involves counting 100 tumor cells in up to 4 high-power fields to derive a mean Ki67 score (Fig. 1). Fields are chosen following an assessment of overall heterogeneity in staining. The final mean Ki67 score consisted of the average of the 2 scoring investigators’ mean Ki67 scores for each case. Maximum Ki67 was assessed by 1 investigator and consisted of the highest-scoring individual field (Fig. 1). This was included because the highest proliferative tumor area may be important for radiation therapy response.

All cases with a discrepancy in initial mean Ki67 score >10% were rescored (15). Further rescores were carried out if the discrepancy remained >10%.

**Study endpoints**

Mean and maximum Ki67 scores were evaluated. Recurrence was defined as patients with biochemical (16) or clinical failure after radiation therapy (BCR). Patients experiencing BCR within 2 years of radiation therapy commencement were excluded because they are more likely to have developed distant metastases than local recurrence due to radiation therapy failure (2). All data pertaining to recurrence was taken from a CHHiP data snapshot (November 9, 2015) in which median follow-up was 62.4 months (interquartile range, 53.9-77.0 months). Nonrecurrence was defined in patients with no evidence of BCR alive at the data snapshot.

![Fig. 1. Scoring Ki67 using the global unweighted method. This case contained 50% high proliferation tumor and 50% low proliferation tumor; therefore, high-power fields were selected for 2 highly proliferative areas and 2 low proliferative areas. In this case the numbers of positive staining cells were as follows: field 1, 39/100; field 2, 33/100; field 3, 5/100; and field 4, 5/100. This gives a mean Ki67 score of 20.5% and a maximum Ki67 score of 39%.](image-url)
Statistical analysis

Agreement in Ki67 scores between the 2 scoring investigators was assessed using Bland-Altman plots to measure the difference between the scores versus the mean of the mean Ki67 scores (17). The concordance correlation coefficient was used to quantify agreement. The difference in the mean Ki67 scores (mean and maximum) between the matched cases and controls by fractionation schedule was compared using paired t tests.

Both Ki67 endpoints were analyzed as continuous variables to maximize statistical power (18). Multivariable conditional logistic regression models were fitted to estimate the prognostic value of Ki67 on the risk of BCR, using the entire Trans-CHHiP case-control study cohort. To determine whether Ki67 predicted BCR by fractionation, a biomarker fractionation interaction term was included. Three comparisons were undertaken to avoid confounding by different recurrence rates across trial arms (74 Gy/37 fractions vs 60 Gy/20 fractions, 74 Gy/37 fractions vs 57 Gy/19 fractions, and 60 Gy/20 fractions vs 57 Gy/19 fractions). Based on an alpha of 0.017, we estimated a power of 75.5%, 74.8%, and 70.0% to detect an interaction between each fractionation schedule and Ki67, respectively (Table E3; available online at www.redjournal.org).

All statistical analysis was conducted using STATA version 13.0 (StataCorp, College Station, TX) and R (version i3863.3.3; R Foundation for Statistical Computing, Vienna).

Results

Patient characteristics

A total of 437 cases were assessed by both scoring investigators. Ki67 scores were provided by both investigators in 400 cases; in 37 cases there was insufficient tumor present. The final matched dataset comprised 173 patients with BCR after start of radiation therapy (cases) and 173 patients without recurrence (controls). Matching was achieved to 100% of relevant criteria in all cases analyzed. Fifty-four patients were excluded because they did not have an appropriate match; these were usually controls with no available matching case. Table 1 shows the distribution of the matching variables and age for the controls and cases.

Agreement in Ki67 scores

Of the total of 400 cases scored by both investigators, in 12 cases (3.0%) the difference in mean Ki67 between the 2 scoring investigators was ≥10% (interquartile range, 11.8%-15.1%). These were rescored by both scoring investigators. All rescores were within the required <10% discrepancy. Scatter plots comparing each scoring investigator’s final scores, and Bland-Altman plots comparing the difference in final score versus the mean Ki67, are shown in Figure 2 (original scores, Fig. E1; available online at www.redjournal.org).

Table 1 Distribution of the matching variables and age, according to fractionation schedule

| Variable | 74 Gy (n = 116, 33.5%) | 60 Gy (n = 104, 30.1%) | 57 Gy (n = 126, 36.4%) |
|----------|------------------------|------------------------|------------------------|
|          | Controls (n = 58) | Cases (n = 58) | Controls (n = 52) | Cases (n = 52) | Controls (n = 63) | Cases (n = 63) |
| PSA (ng/mL) | n | n | % | n | n | % | n | n | % |
| <10 | 17 | 17 | 29.3 | 20 | 20 | 38.5 | 33 | 33 | 52.4 |
| 10-<20 | 37 | 37 | 63.8 | 27 | 27 | 51.9 | 26 | 26 | 41.3 |
| 20 | 4 | 4 | 6.9 | 5 | 5 | 9.6 | 4 | 4 | 6.3 |
| Tumor stage | | | | | | | | | |
| T1 | 11 | 11 | 19.0 | 8 | 8 | 15.4 | 20 | 20 | 31.7 |
| T2 | 42 | 42 | 72.4 | 38 | 38 | 73.1 | 35 | 35 | 55.6 |
| T3 | 5 | 5 | 8.6 | 6 | 6 | 11.5 | 8 | 8 | 12.7 |
| Gleason score | | | | | | | | | |
| ≤6 | 6 | 6 | 10.3 | 5 | 5 | 9.6 | 8 | 8 | 12.7 |
| 3+4 | 31 | 31 | 53.4 | 30 | 30 | 57.7 | 30 | 30 | 47.6 |
| 4+3 | 16 | 16 | 27.6 | 10 | 10 | 19.2 | 15 | 15 | 23.8 |
| >8 | 5 | 5 | 8.6 | 7 | 7 | 13.5 | 10 | 10 | 15.9 |
| Age at randomization (y), mean (SD) | 69.4 (6.3) | 69.8 (6.6) | 68.9 (5.4) | 68.0 (5.8) | 70.1 (6.1) | 68.4 (6.2) |
| PSA (ng/mL) median (IQR) | 12 (8.9-15.8) | 11.9 (9.1-16.2) | 12.2 (8.6-15.1) | 11.6 (8.6-18.1) | 9.6 (7.3-13.0) | 9.7 (7.2-15.0) |

Abbreviations: IQR = interquartile range; PSA = prostate-specific antigen.
The Bland-Altman plots indicate that the difference in score tended to increase as the mean Ki67 score increased. The overall agreement was considered to be good, with a concordance correlation coefficient of 0.74 (95% confidence interval [CI] 0.70-0.78, \( P < .001 \)) for the final scores. For the original scores before rescore, the concordance correlation coefficient was 0.63 (95% CI 0.58-0.68, \( P < .001 \)).

**Prediction of biochemical/clinical recurrence**

Multivariable conditional logistic regression models using the entire Trans-CHHiP case–control study sample showed that both mean Ki67 and maximum Ki67 were statistically significant predictors of BCR (Table 2 and Table E4; available online at www.redjournal.org). For each unit increase in mean Ki67 the odds of BCR is estimated to increase by 9% (odds ratio 1.09, 95% CI 1.04-1.15, \( P = .001 \)), having adjusted for matching variables and age. It is clinically relevant that the prediction of recurrence by mean Ki67 is independent of Gleason grade. The lack of correlation between mean Ki67 and Gleason grade is also displayed in the box and whisker plot (Fig. 3). For the maximum Ki67, the odds of BCR were estimated to increase by 5% for each unit increase in the maximum Ki67 score (odds ratio 1.05, 95% CI: 1.01-1.09, \( P = .006 \)) in the multivariable model.

**Prediction of fraction sensitivity**

The results of interaction tests between either mean or maximum Ki67 and fractionation schedule were not statistically significant for all comparisons (Table 3 and Table E4; available online at www.redjournal.org). The distribution of mean and maximum Ki67 scores according to fractionation schedule and recurrence status, including a statistical comparison of the difference between cases and controls within fractionation arms, is shown in Figure E2 (available online at www.redjournal.org).

**Discussion**

This study measures Ki67 staining indices in localized PCa treated with different radiation therapy fractionation schedules. It indicates that the global unweighted method for scoring Ki67 can be used with good agreement between independent scoring investigators without prior experience of this method. To our knowledge this is the first report using the global unweighted method in PCa. However, it is an established method to aid treatment stratification in breast cancer (19), in which Ki67 is used clinically to distinguish between low proliferation luminal A and higher proliferative luminal B breast cancer subtypes (20).

The statistically significant association between mean Ki67 and prediction of BCR has potential clinical application. Our results require external validation in additional patient cohorts, with particular attention to the spectrum of Ki67 expression in different risk groups and a rigorous assessment of scoring concordance in prostate biopsies across different centers. Patients with high mean Ki67 but otherwise lower risk factors could be recommended longer or more intensive androgen deprivation therapy (ADT),

**Table 2** Odds ratio (OR) for BCR estimated by multivariable conditional logistic regression models (n = 346) using Ki67 as a continuous variable, for mean and maximum Ki67.

| Ki67 biomarker | OR* | 95% CI        | \( P \) |
|---------------|-----|--------------|--------|
| Mean Ki67 scores | 1.09 | 1.04-1.15 | .001   |
| Maximum Ki67 scores | 1.05 | 1.01-1.09 | .006   |

**Abbreviations:** BCR = biochemical or clinical failure after radiation therapy; CI = confidence interval.

* Odds ratios are adjusted for the matching variables and age at randomization.
with possible addition of docetaxel or abiraterone (21). Patients with low mean Ki67 could be reassured that they are likely to have a good prognosis and might be candidates for studies of reduced ADT. This study suggests that Ki67 is of maximal predictive benefit when used as a continuous variable; this method of stratification is used effectively in the clinic for Ki67 and other expression profiling-based algorithms (19, 22).

Our exclusion of patients with BCR less than 2 years after radiation therapy means the estimates of the predictive value of Ki67 are likely to be conservative. Maximum Ki67 was also a statistically significant predictor of BCR, which is worthy of further study because a single-field assessment of 100 cells is quicker than 4 fields for mean Ki67.

The apparent lack of interaction between Ki67 and fractionation schedule also has clinical implications. The range of proliferative indices seen indicates that the predominantly intermediate-risk PCa included in the trial are usually slowly proliferative. However, when including those cancers showing relatively high proliferation rates, there was no suggestion of a detriment using hypofractionated radiation therapy schedules giving 3 Gy per fraction. Other tumor types encompass wider ranges in proliferation and show higher average proliferation (7). Our results should not be interpreted as demonstrating a general lack of association between proliferation and fraction sensitivity. An important confounding factor may be the complex interplay between fraction sensitivity and overall treatment time (23). Additionally, we acknowledge that the statistical power of tests of interaction are low and that a relatively small proportion of high-risk PCa were included in CHHiP.

Of 3216 patients recruited to CHHiP, 3112 (96.7%) were treated with ADT from just after their diagnostic biopsy until completion of radiation therapy. Androgen-deprivation therapy may modulate fraction sensitivity because it can markedly reduce proliferation and affect repair of double-stranded DNA breaks (24). Androgen-deprivation therapy can also inhibit the cell cycle at the G1/S checkpoint as part of induction of senescence (25, 26). This inhibition could restrict use of double-stranded DNA repair pathway homologous recombination, which operates exclusively in S and G2 and is thought to mediate resistance to fraction sensitivity (27, 28). Cells would instead rely on error-prone nonhomologous end-joining, which operates throughout the cell cycle and is important for fraction sensitivity (27, 28). In the PROFIT trial of radiation therapy fractionation, men did not receive ADT and outcomes were similar to those in CHHiP (29). This suggests that ADT does not have a major impact on average fraction sensitivity in PCa; however, ADT may have confounded the interaction between proliferation and BCR according to fractionation schedule in our study.

Our results are supported by a recent report by Pollack et al (30). In this, a single cut-point (11.3%) was used to score Ki67, fractionation schedules differed from those in our study, and there were fewer failure events. However, Ki67 demonstrated independent prediction of prognosis and did not predict fraction sensitivity. It is relevant that Ki67 immunohistochemistry is routinely available and affordable for most pathology laboratories, and automated scoring algorithms are showing potential clinical applicability (31).

This study assessing Ki67 in patients treated with different radiation therapy fractionation schedules reaches

**Table 3** Odds ratio for BCR estimated from multivariable conditional logistic regression models without and with interaction terms between the mean Ki67 scores and fractionation schedules

| Schedules      | Variable | 95%    | P     | P for interaction* |
|----------------|----------|--------|-------|--------------------|
| 74 Gy & 60 Gy  | Mean Ki67| 1.09   | 1.02-1.17 | .007               |
| 74 Gy & 57 Gy  | Mean Ki67| 1.07   | 1.01-1.14 | .03                |
| 60 Gy & 57 Gy  | Mean Ki67| 1.11   | 1.04-1.19 | .001               |

Abbreviations as in Table 2.

Odds ratios are adjusted for matching variables and age at randomisation.

* P value for the interaction between the mean Ki67 scores and fractionation schedules.

**Fig. 3.** Box and whisker plot showing relationship between mean Ki67 and Gleason grade group.
2 conclusions. First, it does not suggest that there is a
detriment to using hypofractionated radiation therapy
schedules in PCa showing relatively high proliferation.
Second, Ki67 is a highly statistically significant biomarker
predicting recurrence, independent of established prog-
nostic factors. Because localized PCa shows diverse clinical
outcomes, Ki67 has a potential clinical application to guide
treatment stratification.

References

1. Ferlay J, Soerjomataram I, Ervik M, et al., editors. Globocan 2012
   v1.0. Cancer Incidence and Mortality Worldwide: IARC Cancerbase
   No. 11. Lyon, France: International Agency for Research on Cancer;
   2013.
2. Lalonde E, Ishkanian AS, Sykes J, et al. Tumour genomic and
   microenvironmental heterogeneity for integrated prediction of 5-year
   biochemical recurrence of prostate cancer: A retrospective cohort
   study. Lancet Oncol 2014;15:1521-1532.
3. Dearealey D, Syndikus I, Mossop H, et al. Conventional versus
   hypofractionated high-dose intensity-modulated radiotherapy for
   prostate cancer: 5-year outcomes of the randomised, non-inferiority,
   phase 3 chipl trial. Lancet Oncol 2016;17:1047-1060.
4. Cancer Genome Atlas Research Network. The molecular taxonomy of
   primary prostate cancer. Cell 2015;163:1011-1025.
5. Verhoven B, Yan Y, Ritter M, et al. Ki-67 is an independent predictor
   of metastasis and cause-specific mortality for prostate cancer patients
   treated on Radiation Therapy Oncology Group (RTOG) 94-08. Int J
   Radiat Oncol Biol Phys 2013;86:317-323.
6. Kirsch DG, Diehn M, Kesarwala AH, et al. The future of radiobiology.
   J Natl Cancer Inst 2017 Nov 3. https://doi.org/10.1093/jnci/djx231.
   [Epub ahead of print]. PMID: 29126306.
7. Somaiah N, Rothkamm K, Yarnold J. Where do we look for markers of
   radiontherapy fraction size sensitivity? Clin Oncol (R Coll Radiol)
   2015;27:570-578.
8. Thames HD Jr, Withers HR, Peters LJ, et al. Changes in early and late
   radiation responses with altered dose fractionation: Implications for dose-
   survival relationships. Int J Radiat Oncol Biol Phys 1982;8:219-226.
9. Epstein JJ, Egevad L, Amin MB, et al. The 2014 International Society of
   Urological Pathology (ISUP) Consensus Conference on Gleason
   Grading of Prostatic Carcinoma: Definition of grading patterns and
   proposal for a new grading system. Am J Surg Pathol 2016;40:244-252.
10. Moch H, Humphrey PA, Ulbright TM, et al. WHO Classification of
    Tumours of the Urinary System and Male Genital Organs. World
    Health Organization Classification of Tumours, Volume 8. Lyon, France:
    WHO/IARC Press; 2016.
11. McCarthy F, Dennis N, Flohr P, et al. High-density tissue microarrays
    from prostate needle biopsies. J Clin Pathol 2011;64:88-90.
12. Polley MY, Leung SC, Gao D, et al. An international study to increase
    concordance in Ki67 scoring. Mod Pathol 2015;28:778-786.
13. Leung SCY, Nielsen TO, Zabaglo L, et al. Analytical validation of a
    standardized scoring protocol for Ki67: Phase 3 of an international
    multicenter collaboration. NPJ Breast Cancer 2016;2:16014.
14. Wei L, Wang I, Lampert E, et al. Intratumoral and intertumoral
    genomic heterogeneity of multifocal localized prostate cancer impacts
    molecular classifications and genomic prognosticators. Eur Urol 2017;
    71:183-192.
15. Niikura N, Masuda S, Kumaki N, et al. Prognostic significance of the
    Ki67 scoring categories in breast cancer subgroups. Clin Breast
    Cancer 2014;14:323-329.e323.
16. Roach M 3rd, Hanks G, Thames H Jr., et al. Defining biochemical
    failure following radiotherapy with or without hormonal therapy in
    men with clinically localized prostate cancer: Recommendations of the
    RTOG-ASTRO Phoenix consensus conference. Int J Radiat Oncol
    Biol Phys 2006;65:965-974.
17. Bland JM, Altman DG. Statistical methods for assessing agreement
    between two methods of clinical measurement. Lancet 1986;1:307-
    310.
18. Denkert C, Budczies J, von Minckwitz G, et al. Strategies for devel-
    oping Ki67 as a useful biomarker in breast cancer. Breast 2015;
    24(Suppl 2):S67-S72.
19. Yeo B, Zagablo L, Hills M, et al. Clinical utility of the IHC4+C score in
    oestrogen receptor-positive early breast cancer: A prospective de-
    cision impact study. Br J Cancer 2015;113:390-395.
20. Coates AS, Winer EP, Goldhirsh A, et al. Tailoring therapies—improving
    the management of early breast cancer: St Gallen International Expert
    Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann
    Oncol 2015;26:1533-1546.
21. James ND, de Bon J, Spears MR, et al. Abiraterone for prostate cancer
    not previously treated with hormone therapy. N Engl J Med
    2017;377:338-351.
22. Harris LN, Ismaila N, McShane LM, et al. Use of biomarkers to
    guide decisions on adjuvant systemic therapy for women with early-
    stage invasive breast cancer: American Society of Clinical Oncology
    clinical practice guideline summary. J Clin Oncol 2016;12:
    384-389.
23. Guillford S, Hall E, Dearealey D. Hypofractionation trials and
    radiobiology of prostate cancer. Oncoscience 2017;4:27-28.
24. Tarish FL, Schultz N, Tangoldi A, et al. Castration radiosensitizes
    prostate cancer tissue by impairing DNA double-strand break repair.
    Sci Transl Med 2015;7:312re311.
25. Burton DG, Gribaldi MG, Munoz A, et al. Androgen deprivation-
    induced senescence promotes outgrowth of androgen-refractory
    prostate cancer cells. Plos One 2013;8:e68003.
26. Kawata H, Kamiakito T, Nakaya T, et al. Stimulation of cellular se-
    nescence processes, including secretory phenotypes and anti-oxidant
    responses, after androgen deprivation therapy in human prostate
    cancer. J Steroid Biochem Mol Biol 2017;165:219-227.
27. Somaiah N, Yamold J, Daley F, et al. The relationship between ho-
    mologous recombination repair and the sensitivity of human epidermis
    to the size of daily doses over a 5-week course of breast radiotherapy.
    Clin Cancer Res 2012;18:5479-5488.
28. Somaiah N, Yamold J, Lagerqvist A, et al. Homologous recombin-
    ation mediates cellular resistance and fraction size sensitivity to radia-
    tion therapy. Radiother Oncol 2013;108:155-161.
29. Cautton CN, Lukka H, Gu CS, et al. Randomized trial of a hypo-
    fractionated radiation regimen for the treatment of localized prostate
    cancer. J Clin Oncol 2017;35:1884-1890.
30. Pollack A, Kwon D, Walker G, et al. Prospective validation of diag-
    nostic tumor biomarkers in men treated with radiotherapy for prostate
    cancer. J Natl Cancer Inst 2017;109:1-8.
31. Abubakar M, Orr N, Daley F, et al. Prognostic value of automated
    Ki67 scoring in breast cancer: A centralised evaluation of 8088 pa-
    tients from 10 study groups. Breast Cancer Res 2016;18:104.